secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2023-01-31T23:59:59+00:00
Accession:  0001193125-23-020343
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha receives FDA feedback on TSHA-120 GAN; sets Rett syndrome milestones for 2023
--------------------------------------------------------------------------------

- FDA acknowledged MFM32 as acceptable endpoint; recommended double-blind placebo-controlled design for TSHA-120 BLA.
- Dosing of first adult Rett patient with TSHA-102 expected H1 2023; initial clinical data also in H1 2023.
- CTA submission to UK MHRA for pediatric Rett syndrome expected mid-2023; IND to FDA planned H2 2023.
- Operational, structural and personnel changes implemented following business review to enhance execution.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523020343/0001193125-23-020343-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523020343/d427060d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-020343

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer